Biotechnology

DiviTum(R) TKa to pursue Gap-fill process for CMS pricing decision

September 28, 2023 5:30 AM

UPPSALA, SE / ACCESSWIRE / September 28, 2023 / Biovica International (STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, today announces that the Center for Medicare & Medicaid Services (CMS) has issued a preliminary CLFS payment decision for DiviTum TKa to pursue the gap-fill process during 2024. The gap-fill process is an established route to an anticipated own PLA pricing code. The process is used for unique tests where there are...

Read more

Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations

September 27, 2023 5:45 PM

Start of industrial development of Sarconeos (BIO101) with a view to market access in severe forms of Covid-19 (COVA) Approvals to start the Phase 3 trial in the United States and Belgium in sarcopenia (SARA), a world first, opening up the prospect of partnerships Cash position and secured financing giving visibility of over 12 months PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 27,2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth...

Read more

BioInvent to Hold Two Poster Presentations at SITC 38th Annual Meeting

September 27, 2023 9:15 AM

LUND, SE / ACCESSWIRE / September 27, 2023 / BioInvent International (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it will hold two poster presentations on its anti-tumor necrosis factor receptor 2 (TNFR2) programs at the Society of Immunotherapy for Cancer (SITC) 38th Annual Meeting, held November 3-5, 2023, in San Diego,...

Read more

Hyris Supports Researchers and Developers to Launch Testing Kits via New Onboarding Programs

September 27, 2023 5:00 AM

Following the launch of its Marketplace in 2022, Hyris continues to leverage the AI capabilities of its genetic testing platform, renowned for its adaptability, to support both researchers and kit developers worldwide. New onboarding programs enable emerging players to accelerate their go-to-market, as well as established manufacturers and diagnostic providers to integrate their portfolio with ease, maximizing their cost-per-value strategy....

Read more

BioStem Receives IRB Approval for Clinical Study to Evaluate Vendaje(R) in Diabetic Foot Ulcers

September 26, 2023 8:30 AM

POMPANO BEACH, FL / ACCESSWIRE / September 26, 2023 / BioStem Technologies Inc. (OTC PINK:BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today the approval of an Investigational Review Board (IRB) sanctioned clinical study. This study aims to investigate the utilization and effects of Vendaje in diabetic patients...

Read more

Vaso Corporation Announces Upgrade to OTCQX Best Market from OTCQB Venture Market

September 25, 2023 4:15 PM

PLAINVIEW, NY / ACCESSWIRE / September 25, 2023 / Vaso Corporation ("Vaso") (OTCQB:VASO) today announced that its application to trade on the OTCQX Best Market has been approved by OTC Markets Group, with the beginning of trading on OTCQX expected to be on September 26, 2023. The OTCQX Market provides investors with a premium U.S. public market to research and trade the shares of investor-focused companies. Graduating from OTCQB Venture Market,...

Read more

Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)

September 25, 2023 1:30 AM

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 25, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, and Skyepharma, a French pharmaceutical company specializing in...

Read more

Vibrant Wellness Unveils Groundbreaking Toxin Genetics Test for Personalized Detox Protocols

September 22, 2023 9:00 AM

Vibrant Wellness introduces the Toxin Genetics Test, a cutting-edge addition to its suite of advanced functional lab tests. This revolutionary tool assesses genetic biomarkers pivotal to the body's detox process, aiding healthcare professionals in designing individualized detoxification plans. SANTA CLARA, CA / ACCESSWIRE / September 22, 2023 / Vibrant Wellness, a pioneer in advanced functional lab testing, today announced the launch of its...

Read more

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

September 22, 2023 8:30 AM

Expects to launch and complete a Phase 1 trial in Q4 2023 Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023 BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc., (NASDAQ:HILS), a biotechnology company developing innovative therapeutic candidates in rare immune, inflammatory and oncologic diseases announced a corporate name change to Tharimmune, Inc., ("Tharimmune"). The corporate name...

Read more

BioInvent recruits first patient in Phase 2a trial of single agent BI-1808 for the treatment of advanced malignancies

September 22, 2023 2:20 AM

LUND, SWEDEN / ACCESSWIRE / September 22, 2023 / BioInvent International (STO:BINV) Strong interim safety data on BI-1808 as single agent reported in June 2023 Next data readout, from Phase 1 combination part of trial, to come in H1 2024 BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy,...

Read more

Abivax presents first-half 2023 financial results

September 21, 2023 2:00 PM

PARIS, FRANCE / ACCESSWIRE / September 21, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announces today its 2023 half-year financial results, as of June 30, 2023. The interim financial statements for...

Read more

Mitochem Therapeutics Receives $900,000 Foundation Fighting Blindness Award To Study Target and Mechanism of Action in Retinal Degeneration Diseases

September 21, 2023 11:30 AM

CHARLESTON, SC / ACCESSWIRE / September 21, 2023 / MitoChem Therapeutics, Inc., a privately held company developing therapies for diseases involving mitochondrial dysfunction, announced today a $900,000 award from the Foundation Fighting Blindness. This funding will allow MitoChem to advance its understanding of the mechanism of action of their lead compound in treating a range of retinal degenerative diseases. One of the contributing factors...

Read more

M2Bio Sciences Closes JDAX Acquisition

September 21, 2023 10:00 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / September 21, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is delighted to share the following consequential update: Regarding the M2Bio Sciences Press Release...

Read more

Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD

September 21, 2023 9:10 AM

DehydraTECH-powered GLP-1 drugs will be evaluated for potential improvements such as: Reduced side effects; Enhanced weight loss; Improved health outcomes for diabetes and other conditions; Improved oral bioavailability; Reduced cost. KELOWNA, BC / ACCESSWIRE / September 21, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces its intention to launch...

Read more

Seraxis Announces Closing of Second VC Tranche and Successful Completion of Preclinical Studies of Pancreatic Organoids From Seraxis’ Novel Pancreas-Derived Stem Cells

September 21, 2023 9:00 AM

Leadership team expanded with addition of Chief Corporate Development Officer, Ted Hibben, a 25-year venture-stage business development biotherapeutic industry veteran Total venture funding tops $50M to date GERMANTOWN, MD / ACCESSWIRE / September 21, 2023 / Seraxis Inc., a cell therapy company developing a pancreatic organoid cure to transform the lives of patients with Type 1 and insulin-requiring Type 2 diabetes, today announced the closing...

Read more

Ondine Biomedical Inc. Announces Montreal Heart Institute pilots Steriwave

September 21, 2023 2:00 AM

Montreal Heart Institute pilots Steriwave The world-renowned Montreal Heart Institute and Hôpital Fleurimont, University of Sherbrooke (CHUS) in Sherbrooke, Quebec are piloting nasal photodisinfection to prevent post-operative infections in an era of rising antibiotic resistance. 2022 SHEA guidelines elevated nasal decolonization to an essential practice for orthopedic and cardiothoracic surgical procedures. ·The topical antibiotic commonly used...

Read more

Genflow Biosciences PLC Announces Company Update

September 20, 2023 2:00 AM

Successful first regulatory interaction with the Federal Agency for Medicines and Health Products (FAHMP) And Internal Debt Restructuring First regulatory agency interaction results in recommendation to commence Phase I/II Clinical Trial in NASH Patients LONDON, UK / ACCESSWIRE / September 20, 2023 / Genflow Biosciences Plc ("Genflow" or "the Company") The Company (LSE:GNF) (OTCQB:GENFF), today announces the receipt of written comments from the...

Read more

First Patient Treated in Innovative Clinical Study 'Amelia-1', Testing the Novel Investigational Drug Evexomostat Plus a PI3K Inhibitor in Late-Stage Breast Cancer Patients

September 19, 2023 10:00 AM

Amelia™-1 Study is testing if evexomostat can improve patients' safety and clinical response to a PI3K inhibitor plus an estrogen receptor degrader. Evexomostat, a novel MetAP2 inhibitor, controlled PI3K-induced hyperglycemia in the first study patient, consistent with pre-clinical data. Further, ctDNA data shows no evidence of residual PIK3CA mutation in blood after 6 weeks of treatment. CAMBRIDGE, MA / ACCESSWIRE / September 19, 2023 /...

Read more

Biovica signs US agreement with leading healthcare provider in Arizona

September 19, 2023 6:55 AM

UPPSALA, SWEDEN / ACCESSWIRE / September 19, 2023 / Biovica today announces that the company has entered into a commercial agreement with a leading healthcare provider that operates more than 30 hospital laboratories, primarily located in Arizona. The agreement will ensure access to DiviTum® TKa for patients across the partners extensive network covering the southwest region of the United States. This agreement marks Biovica's first commercial...

Read more

Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19

September 19, 2023 1:40 AM

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 19, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from...

Read more